Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.54 |
| ▸ | FLT3 | P36888 | 11/20 | 0.54 |
| ▸ | KIT | P10721 | 10/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.52 |
| ▸ | ULK1 | O75385 | 3/20 | 0.51 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26506373 | 0.88 | EGFR (0.61) | CHEK1FLT3KITALKINSR | |
| SCHEMBL27087853 | 0.87 | ULK1 (0.64) | CHEK1FLT3KITALKINSR | |
| SCHEMBL29989366 | 0.87 | ULK1 (0.64) | CHEK1FLT3KITALKINSR | |
| SCHEMBL26506372 | 0.85 | SYK (0.70) | SYK | |
| SCHEMBL26506279 | 0.85 | FLT3 (0.70) | CHEK1FLT3KITMAP3K7RPS6KB1 | |
| SCHEMBL27087841 | 0.84 | ULK1 (0.60) | CHEK1FLT3KITALKINSR | |
| SCHEMBL29990414 | 0.84 | ULK1 (0.60) | CHEK1FLT3KITALKINSR | |
| SCHEMBL29156183 | 0.82 | ULK1 (0.59) | CHEK1FLT3KITALKINSR | |
| SCHEMBL26506309 | 0.81 | FLT3 (0.60) | CHEK1FLT3KITMAP3K7RPS6KB1 | |
| SCHEMBL14837275 | 0.81 | SYK (0.73) | ALKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | CHEK1 53/4885FLT3 1706/4885KIT 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.